Trial Profile
Thromboprophylaxis With Fondaparinux of Deep Vein Thrombosis and Pulmonary Embolism in the Acutely-ill Medical Inpatients With Thrombocytopenia
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms FAITH
- 14 Jul 2021 Status changed from active, no longer recruiting to discontinued.
- 07 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 07 Aug 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.